Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White Sells 2,817 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White sold 2,817 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $30.79, for a total transaction of $86,735.43. Following the transaction, the chief financial officer now owns 38,335 shares of the company’s stock, valued at approximately $1,180,334.65. The trade was a 6.85 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Akero Therapeutics Trading Down 0.5 %

Shares of Akero Therapeutics stock opened at $28.89 on Friday. The company has a 50-day moving average of $30.81 and a two-hundred day moving average of $27.13. Akero Therapeutics, Inc. has a 12-month low of $15.32 and a 12-month high of $37.00. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. The stock has a market cap of $2.02 billion, a PE ratio of -7.70 and a beta of -0.23.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.15). On average, research analysts anticipate that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AKRO. Citigroup assumed coverage on shares of Akero Therapeutics in a report on Monday, November 18th. They set a “buy” rating and a $65.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Akero Therapeutics in a research report on Monday, November 18th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $46.83.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in AKRO. SG Americas Securities LLC increased its holdings in Akero Therapeutics by 191.2% during the 2nd quarter. SG Americas Securities LLC now owns 14,517 shares of the company’s stock valued at $341,000 after acquiring an additional 9,532 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Akero Therapeutics by 32.8% in the second quarter. Bank of New York Mellon Corp now owns 251,234 shares of the company’s stock valued at $5,894,000 after purchasing an additional 61,988 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Akero Therapeutics by 30.3% during the 2nd quarter. Rhumbline Advisers now owns 107,338 shares of the company’s stock worth $2,518,000 after purchasing an additional 24,940 shares in the last quarter. TD Asset Management Inc raised its position in shares of Akero Therapeutics by 23.7% during the 2nd quarter. TD Asset Management Inc now owns 154,592 shares of the company’s stock worth $3,627,000 after purchasing an additional 29,600 shares during the last quarter. Finally, Quest Partners LLC lifted its stake in Akero Therapeutics by 22,021.1% in the 2nd quarter. Quest Partners LLC now owns 12,609 shares of the company’s stock valued at $296,000 after buying an additional 12,552 shares in the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.